Kanglin Biotec (Hangzhou) Co., Ltd. was founded in 2015 with the goal of translating advances in genetic science into curative treatments for previously incurable diseases. We believe in the groundbreaking potential of genetic medicine and have set ourselves the goal of developing first-in-class and best-in-class gene therapies. Guided by scientific innovation, our aspiration is very simple, to make good medicine for patients.

We are currently developing gene therapies for devastating diseases such as β-thalassemia, Parkinson’s disease, AIDS, hemophilia and others. Years of dedicated research and development have yielded initial results. Our AIDS functional cure project has received support from the National Science and Technology Major Project as well as the Key Research and Development Projects of Zhejiang Province. Exploratory trials of our investigational β-thalassemia candidate have shown promising results, generating efficacy and safety data that indicates best-in-class potential. With these achievements affirming our efforts, we feel empowered to keep working towards our goal and to contribute to the scientific advances that aim to cure what was once deemed “incurable”.